3 Stocks Pushing The Health Care Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 89 points (-0.5%) at 16,857 as of Wednesday, June 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,007 issues advancing vs. 1,935 declining with 173 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the sector include Grifols ( GRFS), down 1.6%, Medtronic ( MDT), down 1.1%, Valeant Pharmaceuticals International ( VRX), down 1.1%, Biogen Idec ( BIIB), down 1.0% and Novartis ( NVS), down 0.9%. Top gainers within the sector include Alnylam Pharmaceuticals ( ALNY), up 4.7%, Gilead ( GILD), up 2.2%, Cigna ( CI), up 1.7%, WellPoint ( WLP), up 1.4% and AbbVie ( ABBV), up 1.2%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. CR Bard ( BCR) is one of the companies pushing the Health Care sector lower today. As of noon trading, CR Bard is down $2.90 (-2.1%) to $138.15 on heavy volume. Thus far, 879,639 shares of CR Bard exchanged hands as compared to its average daily volume of 793,700 shares. The stock has ranged in price between $137.95-$140.99 after having opened the day at $140.98 as compared to the previous trading day's close of $141.05.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard has a market cap of $11.3 billion and is part of the health services industry. Shares are up 5.3% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts that rate CR Bard a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates CR Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CR Bard Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, HCA Holdings ( HCA) is down $0.60 (-1.1%) to $54.66 on average volume. Thus far, 1.5 million shares of HCA Holdings exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $54.00-$55.17 after having opened the day at $55.05 as compared to the previous trading day's close of $55.26.

HCA Holdings, Inc., through its subsidiaries, provides health care services. HCA Holdings has a market cap of $24.6 billion and is part of the health services industry. Shares are up 15.8% year-to-date as of the close of trading on Tuesday. Currently there are 15 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates HCA Holdings as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins. Get the full HCA Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Abbott Laboratories ( ABT) is down $0.47 (-1.2%) to $40.06 on light volume. Thus far, 1.8 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 6.7 million shares. The stock has ranged in price between $39.93-$40.49 after having opened the day at $40.24 as compared to the previous trading day's close of $40.53.

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $60.3 billion and is part of the health services industry. Shares are up 5.7% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and weak operating cash flow. Get the full Abbott Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Stocks Rise Sharply, Facebook Ignites a Nasdaq Rally

Stocks Rise Sharply, Facebook Ignites a Nasdaq Rally

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations